AU2021200638B2 - Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists - Google Patents

Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists Download PDF

Info

Publication number
AU2021200638B2
AU2021200638B2 AU2021200638A AU2021200638A AU2021200638B2 AU 2021200638 B2 AU2021200638 B2 AU 2021200638B2 AU 2021200638 A AU2021200638 A AU 2021200638A AU 2021200638 A AU2021200638 A AU 2021200638A AU 2021200638 B2 AU2021200638 B2 AU 2021200638B2
Authority
AU
Australia
Prior art keywords
oxpapc
lps
caspase
dcs
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021200638A
Other languages
English (en)
Other versions
AU2021200638A1 (en
Inventor
Jonathan C. Kagan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016206965A external-priority patent/AU2016206965C1/en
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to AU2021200638A priority Critical patent/AU2021200638B2/en
Publication of AU2021200638A1 publication Critical patent/AU2021200638A1/en
Application granted granted Critical
Publication of AU2021200638B2 publication Critical patent/AU2021200638B2/en
Priority to AU2024219454A priority patent/AU2024219454A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021200638A 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists Active AU2021200638B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021200638A AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2024219454A AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562102245P 2015-01-12 2015-01-12
US62/102,245 2015-01-12
AU2016206965A AU2016206965C1 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
PCT/US2016/012994 WO2016115097A2 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2021200638A AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
AU2016206965A Division AU2016206965C1 (en) 2015-01-12 2016-01-12 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024219454A Division AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Publications (2)

Publication Number Publication Date
AU2021200638A1 AU2021200638A1 (en) 2021-03-04
AU2021200638B2 true AU2021200638B2 (en) 2024-06-06

Family

ID=56406560

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021200638A Active AU2021200638B2 (en) 2015-01-12 2021-02-01 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
AU2024219454A Pending AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024219454A Pending AU2024219454A1 (en) 2015-01-12 2024-09-06 Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists

Country Status (6)

Country Link
US (7) US20180318414A1 (enExample)
EP (1) EP3244923B1 (enExample)
JP (7) JP2018501322A (enExample)
AU (2) AU2021200638B2 (enExample)
CA (1) CA2973585A1 (enExample)
WO (1) WO2016115097A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501322A (ja) 2015-01-12 2018-01-18 チルドレンズ メディカル センター コーポレーション トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
EP3538138A1 (en) * 2016-11-14 2019-09-18 Dana Farber Cancer Institute, Inc. Compositions and methods of treating cancer
AU2020253403A1 (en) * 2019-03-29 2021-10-28 Children's Medical Center Corporation Targeted synergistic cancer immunotherapy
WO2021071977A1 (en) * 2019-10-07 2021-04-15 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
US20230076515A1 (en) * 2019-11-18 2023-03-09 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
CN114980928B (zh) * 2019-11-18 2025-03-07 儿童医学中心公司 过度活化的树突状细胞可实现持久的基于过继性细胞转移的抗肿瘤免疫
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026384A1 (en) * 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
ATE207366T1 (de) 1993-12-24 2001-11-15 Merck Patent Gmbh Immunokonjugate
AU2003243806A1 (en) * 2002-07-15 2004-02-02 Bernd Binder Lipid oxidation products for inhibiting inflammation
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
EP2077821B1 (en) * 2006-10-12 2019-08-14 The University Of Queensland Compositions and methods for modulating immune responses
KR101408445B1 (ko) 2009-07-27 2014-06-17 가부시키가이샤 고베 세이코쇼 배선 구조 및 그 제조 방법 및 배선 구조를 구비한 표시 장치
US20130108661A1 (en) 2010-02-05 2013-05-02 Mount Sinai School Of Medicine Methods and compositions for cancer immunotherapy using flagellin-tumor associated antigen fusion protein expressing tumor cells
WO2011136828A1 (en) 2010-04-27 2011-11-03 The Johns Hopkins University Immunogenic compositions and methods for treating neoplasia
CA2840170A1 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CA2858789C (en) * 2011-12-12 2020-09-22 Vascular Biogenics Ltd. Treatment of inflammation
WO2014164699A1 (en) 2013-03-11 2014-10-09 The Regents Of The University Of California Herpes virus vaccines and treatments
WO2015091787A1 (en) 2013-12-18 2015-06-25 Julius-Maximilians-Universität Würzburg Galactose oxidase treatment of dendritic cells to improve their immunogenicity
JP2018501322A (ja) 2015-01-12 2018-01-18 チルドレンズ メディカル センター コーポレーション トール様受容体４アンタゴニストの炎症促進性およびアジュバント機能
EP3291821A4 (en) 2015-05-07 2019-03-20 Baylor College of Medicine IMMUNOTHERAPY WITH DENDRITIC CELLS
MA44252A (fr) 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation
AU2017289450B2 (en) 2016-06-27 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Therapeutic antitumor combination of a TLR4 ligand with other treatments
WO2018067302A2 (en) 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
CA3098868A1 (en) 2018-05-03 2019-11-07 L.E.A.F. Holdings Group Llc Carotenoid compositions and uses thereof
WO2021071977A1 (en) 2019-10-07 2021-04-15 Northwest Biotherapeutics, Inc. In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response
US20230076515A1 (en) 2019-11-18 2023-03-09 Children's Medical Center Corporation Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy
CN114980928B (zh) 2019-11-18 2025-03-07 儿童医学中心公司 过度活化的树突状细胞可实现持久的基于过继性细胞转移的抗肿瘤免疫

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000026384A1 (en) * 1998-11-03 2000-05-11 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Lps with reduced toxicity from genetically modified gram negative bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNAPP, S. et al. "Oxidized Phospholipids Inhibit Phagocytosis and Impair Outcome in Gram-Negative Sepsis In Vivo", The Journal of Immunology, 2007, Vol. 178, pages 993-1001 *

Also Published As

Publication number Publication date
AU2016206965A1 (en) 2017-08-31
WO2016115097A2 (en) 2016-07-21
US20240415957A1 (en) 2024-12-19
AU2021200638A1 (en) 2021-03-04
US11351250B2 (en) 2022-06-07
US20230053338A1 (en) 2023-02-23
JP2021059571A (ja) 2021-04-15
JP2023055883A (ja) 2023-04-18
EP3244923C0 (en) 2025-10-01
JP7410845B2 (ja) 2024-01-10
AU2016206965B2 (en) 2021-03-04
US12070499B2 (en) 2024-08-27
WO2016115097A3 (en) 2016-09-09
US12053522B2 (en) 2024-08-06
JP2018501322A (ja) 2018-01-18
JP2021059570A (ja) 2021-04-15
US20200405847A1 (en) 2020-12-31
JP7410846B2 (ja) 2024-01-10
JP7719815B2 (ja) 2025-08-06
EP3244923A2 (en) 2017-11-22
US20250025552A1 (en) 2025-01-23
JP7719816B2 (ja) 2025-08-06
AU2024219454A1 (en) 2024-10-03
US20230042429A1 (en) 2023-02-09
CA2973585A1 (en) 2016-07-21
US11400153B2 (en) 2022-08-02
JP2023055880A (ja) 2023-04-18
JP2025094038A (ja) 2025-06-24
US20200405848A1 (en) 2020-12-31
US20180318414A1 (en) 2018-11-08
EP3244923A4 (en) 2018-09-05
EP3244923B1 (en) 2025-10-01
JP2025090801A (ja) 2025-06-17

Similar Documents

Publication Publication Date Title
AU2021200638B2 (en) Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
Chuang et al. Adjuvant effect of toll-like receptor 9 activation on cancer immunotherapy using checkpoint blockade
US10155014B2 (en) Cyclic di-AMP induction of type I interferon
Gambuzza et al. Targeting Toll-like receptors: emerging therapeutics for multiple sclerosis management
CN112888707A (zh) T细胞受体构建体及其用途
US11027017B2 (en) PCI method for generating immune respose to antigenic molecule using checkpoint inhibitor and TLR3 ligand
C Junquera et al. Recent advances in the development of anti-Infective prophylactic and/or therapeutic agents based on toll-like receptor (TLRs)
Lalor et al. An immunoregulatory amphipathic peptide derived from Fasciola hepatica helminth defense molecule (FhHDM‐1. C2) exhibits potent biotherapeutic activity in a murine model of multiple sclerosis
WO2023097237A2 (en) Cytosolic bacterial pathogens attenuated for spread from tumors and methods of use thereof
HK40053747A (en) T cell receptor constructs and uses thereof
Wilson et al. Strategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants
WO2017098281A1 (en) Therapeutic agents
WO2010024118A1 (ja) カスパーゼリクルートメントドメインを応用した新規リコンビナントタンパク及びその用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)